Citi said that while it understands these concerns, BAE Systems has similar expected profit growth to US peers, better free ...

Analysts at Berenberg lowered their target price on drugmaker GSK from £18.20 to £16.00 on Monday after hosting chief ...

Although the FDA has expanded approvals for two respiratory syncytial virus (RSV) vaccines to include high-risk young and ...

Learn about this vaccine that protects against a common seasonal virus that can sometimes cause severe disease, with info on ...

GSK PLC said on Friday that Japan's Ministry of Health, Labour & Welfare has approved the expansion of its Arexvy re ... Subscribe now to see this Premium News article from Alliance News ...

The European Commission (EC) has granted approval for a single-vial, fully liquid presentation of GSK's Menveo vaccine ...

GSK’s third-quarter Vaccine sales declined 15% due to lower sales of its RSV vaccine Arexvy and shingles vaccine, Shingrix. Arexvy generated £188 million during the quarter, down 72% year over ...

GlaxoSmithKline (GSK – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Justin Smith from ...

The company recently reported approval from Japan's Ministry of Health, Labour and Welfare to extend the indication of its respiratory syncytial virus vaccine, Arexvy, to individuals aged 50 to 59 ...

Sales of GSK's respiratory syncytial virus (RSV) vaccine Arexvy slumped 72% in the third quarter of this year, as narrower recommendations on its use in the US started to have an effect.

The FDA has approved GSK’s Arexvy shot for the prevention of lower respiratory tract disease caused by RSV in individuals 60 years of age and older, shortly after it was recommended for approval ...